Skip to main content

Contineum Therapeutics, Inc 10-Q for FY2026 Q3

Contineum Therapeutics, Inc. (CTNM)

10-Q 2026-11-03 For: 2026-09-30
View Original
Added on November 03, 2026

About this 10-Q

Contineum Therapeutics, Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

PIPE-307/JNJ-89495120 did not achieve its primary efficacy endpoint in the September 2026 MOONLIGHT-1 trial, while PROPEL-IPF dosing began in the first quarter of 2026. The Company reported $244.5 million in cash, cash equivalents and marketable securities at September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$18.7M
compared with a net loss of $12.79M a year earlier
Diluted EPS
-$0.49
compared with -$0.45 a year earlier